Company Overview
Aurora Cannabis Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products, operating primarily within Canada and internationally through its Canadian Cannabis and Plant Propagation segments. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which defines its role in providing pharmaceutical-grade cannabinoid products to medical markets. Aurora Cannabis Inc. currently holds a market capitalization of $193.95M and reports an annual revenue of $373.12M, though the employee count is not publicly disclosed in the available data. The valuation of $193.95M relative to the annual revenue of $373.12M indicates that the market values the company at approximately 0.52 times its sales, suggesting a premium pricing structure relative to book value while reflecting the capital-intensive nature of its operations in the specialty drug manufacturing space.
Financial Health
The company reported a revenue of $373.12M and a net income of $-83,512,000 over the trailing twelve months, a significant disparity that reveals a cost structure where operating expenses substantially exceed gross profit margins. Despite the net loss, the entity generated an EBITDA of $-32,735,000, indicating that while the bottom line is negative due to non-operating factors or interest expenses, the core operational earnings before interest and taxes remain in a similar negative territory. The business demonstrated a free cash flow of $11.86M, which provides a crucial layer of financial flexibility that allows the company to meet obligations or fund operations without immediate reliance on external equity issuance. Analyzing the profit margins reveals a gross margin of 36.0%, an operating margin of 2.3%, and a profit margin of -22.5%, where the negative profit margin highlights the impact of high overhead costs or interest expenses on the final profitability. The balance sheet shows a cash position of $108.45M against total debt of $101.00M, resulting in a debt-to-equity ratio of 17.79, which indicates a highly leveraged balance sheet where debt obligations are nearly equal to liquid assets. Liquidity is supported by a current ratio of 3.06, suggesting the company possesses sufficient current assets to cover its short-term liabilities more than three times over. Return on Equity stands at -15.5% and Return on Assets is -4.4%, metrics that collectively reveal that management is currently utilizing equity and assets to generate losses rather than positive returns on capital invested.
Valuation Assessment
The valuation metrics present a forward P/E of -31.09 and a trailing P/E of N/A, implying that the market is pricing the stock based on future expectations rather than historical earnings, a common scenario for companies in a turnaround phase or those currently unprofitable. The price-to-book ratio is 0.50, indicating that the market is valuing the company at half of its book value, which suggests a deep discount relative to the net asset value but does not necessarily imply undervaluation given the negative earnings. Alternative valuation metrics such as the price-to-sales ratio of 0.52 and an EV/EBITDA of -6.66 suggest that the market is focusing on revenue generation and market share rather than immediate profitability or earnings power. The stock has a 52-week high of $6.67 and a 52-week low of $3.21, and while the specific current price is not provided in the facts, the range defines the volatility envelope within which the stock has traded over the last year. The beta of 1.30 indicates that the stock is expected to be 30% more volatile than the broader market, reflecting the high-risk profile associated with the cannabis sector and the company's specific financial leverage.
Growth & Income
Revenue growth year-over-year is 6.8%, while earnings growth year-over-year is -94.7%, showing that earnings are shrinking at a much faster rate than revenue is expanding, which implies that the company is facing rising costs, margin compression, or one-time charges that are outpacing top-line growth. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are retained within the company to fund operations, debt reduction, or potential future growth initiatives rather than being distributed to shareholders. The absence of a dividend yield confirms that the company reinvests its resources internally to sustain its production and distribution networks in a competitive market. The overall growth and income profile is characterized by moderate top-line expansion coupled with significant earnings contraction and a reliance on internal cash generation to support a highly leveraged capital structure without distributing income to investors.